Effect of murine recombinant interleukin‐5 on the cell population in guinea‐pig airways

1 An intratracheal injection of murine recombinant interleukin 5 (mrIL‐5, 2–15 μg/0.25 ml/animal) induced a dose‐dependent increase in the number of macrophages, eosinophils, neutrophils and epithelial cells in the bronchoalveolar lavage fluid (BALF) of guinea‐pigs 24 h after administration. Bovine serum albumin (15 μg/0.25 ml/animal), used as a reference material, did not cause any change of this type. 2 The intratracheal administration of mrIL‐5 at a dose of 15 μg showed a tendency to increase the number of these pulmonary inflammatory cells and epithelial cells in the BALF at 12 h with a significant increase observed at 24 h. 3 Prednisolone (20 mg kg−1, i.p.) inhibited the mrIL‐5‐induced increase in macrophages, eosinophils, neutrophils and epithelial cells. Ketotifen (2 mg kg−1, i.p.) reduced the mrIL‐5‐induced increase in the eosinophil, neutrophil and epithelial cell populations. The simultaneous injection of 2% disodium cromoglycate (DSCG) into the trachea prevented the mrIL‐5‐induced increase in the number of airway epithelial cells, without affecting changes in the other inflammatory leukocytes. 4 These results suggest that mrIL‐5 is a potent inducer of lung inflammation, in terms of increased inflammatory leukocytes and epithelial cells in guinea‐pig BALF. Prednisolone, DSCG and ketotifen are effective against mrIL‐5‐induced pulmonary inflammation, especially the desquamation of bronchial epithelial cells.

[1]  H. Smith,et al.  Effect of the Selective Leukotriene B4 Antagonists U‐75302 and Ly255283 on Bronchoalveolar Eosinophilia Induced by Inhalation of Leukotriene B4 or Allergen in Brown‐Norway Rats , 1991, Annals of the New York Academy of Sciences.

[2]  S. Motojima,et al.  [The participation of epithelial desquamation in the increase of bronchial hyperresponsiveness after antigen challenge in patients with bronchial asthma]. , 1990, Arerugi = [Allergy].

[3]  S. Sanjar,et al.  Pretreatment with rh‐GMCSF, but not rh‐IL3, enhances PAF‐induced eosinophil accumulation in guinea‐pig airways , 1990, British journal of pharmacology.

[4]  S. Sanjar,et al.  Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea‐pigs: the effect of anti‐asthma drugs , 1990, British journal of pharmacology.

[5]  A. Kay,et al.  Eosinophils and T-lymphocytes in late-phase allergic reactions. , 1990, The Journal of allergy and clinical immunology.

[6]  S. Sanjar,et al.  Eosinophil accumulation in pulmonary airways of guinea‐pigs induced by exposure to an aerosol of platelet‐activating factor: effect of anti‐asthma drugs , 1990, British journal of pharmacology.

[7]  S. Sanjar,et al.  Human recombinant lymphokines and cytokines induce pulmonary eosinophilia in the guinea pig which is inhibited by ketotifen and AH 21-132. , 1990, International archives of allergy and applied immunology.

[8]  J. Oostveen,et al.  Effect of the selective leukotriene B4 antagonist U-75302 on antigen-induced bronchopulmonary eosinophilia in sensitized guinea pigs. , 1989, The American review of respiratory disease.

[9]  P. Barnes,et al.  New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. , 1989, The Journal of allergy and clinical immunology.

[10]  M. Jordana,et al.  Late-phase airway reaction and inflammation. , 1989, The Journal of allergy and clinical immunology.

[11]  P. Vanhoutte,et al.  Epithelium-derived relaxing factor(s) and bronchial reactivity. , 1988, The American review of respiratory disease.

[12]  S. Holgate,et al.  The effect of cromolyn sodium and albuterol on early and late phase bronchoconstriction and airway leukocyte infiltration after allergen challenge of nonanesthetized guinea pigs. , 1988, The American review of respiratory disease.

[13]  P. Braquet,et al.  The effect of the selective PAF antagonist BN 52021 on PAF- and antigen-induced bronchial hyper-reactivity and eosinophil accumulation. , 1988, European journal of pharmacology.

[14]  C. Sanderson,et al.  Human eosinophil hematopoiesis studied in vitro by means of murine eosinophil differentiation factor (IL5): production of functionally active eosinophils from normal human bone marrow. , 1988, Blood.

[15]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[16]  R. Rylander,et al.  Modulation of pulmonary inflammation after endotoxin inhalation with a platelet-activating factor antagonist (48740 RP). , 1988, International archives of allergy and applied immunology.

[17]  R. Coffman,et al.  Isolation and characterization of lymphokine cDNA clones encoding mouse and human IgA-enhancing factor and eosinophil colony-stimulating factor activities: relationship to interleukin 5. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Honjo,et al.  Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Gleich,et al.  The eosinophil and the pathophysiology of asthma. , 1986, The Journal of allergy and clinical immunology.

[20]  S. Swain.  Role of BCGFII in the differentiation to antibody secretion normal and tumor B cells. , 1985, Journal of immunology.

[21]  A. Tominaga,et al.  Antigen-induced T cell-replacing factor (TRF). III. Establishment of T cell hybrid clone continuously producing TRF and functional analysis of released TRF. , 1980, Journal of immunology.